Clinical trial SYD985.004
A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Synthon Biopharmaceuticals |
| EudraCT Identifier | 2019-002937-12 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04235101 |
| Inclusion criteria | RECIST v1.1 |
| Last update |